1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc.; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit the uptake of glucose by intestinal wall cells; 5. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels.

Competitive angiotensin converting enzyme inhibitors prevent angiotensin I from converting to angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. They can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, they can reduce pulmonary capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time. They can be secreted through breast milk and can pass through the placenta.

This product is a competitive angiotensin converting enzyme inhibitor, which prevents angiotensin I from converting into angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. This product can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, this product can also reduce pulmonary capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time. This product can be secreted through breast milk and can pass through the placenta.

This product has both histamine H1 receptor antagonism and the effect of inhibiting the release of allergic reaction mediators. It not only has a strong anti-allergic effect, but also has a longer duration of efficacy. Therefore, it is more effective in preventing various bronchial asthma attacks and exogenous asthma than endogenous asthma.

This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity, promoting the secretion of pulmonary surfactant, increasing bronchial ciliary movement, and making sputum easier to cough up.

This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity, promoting the secretion of pulmonary surfactant, increasing bronchial ciliary movement, and making sputum easier to cough up.

This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity, promoting the secretion of pulmonary surfactant, increasing bronchial ciliary movement, and making sputum easier to cough up.

This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity, promoting the secretion of pulmonary surfactant, increasing bronchial ciliary movement, and making sputum easier to cough up.

This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity, promoting the secretion of pulmonary surfactant, increasing bronchial ciliary movement, and making sputum easier to cough up.

It has a direct relaxant effect on the smooth muscles of the respiratory tract, increases the intracellular cAMP content by inhibiting phosphodiesterase, and part of its effect comes from the release of endogenous adrenaline and norepinephrine. As a purine receptor blocker, it can counteract the contractile effect of adenine and other substances on the respiratory tract, and can enhance the contractility of the diaphragm to improve respiratory function.